41 Serious Infections and Associated Risk Factors in Patients Receiving Infliximab and Immunotherapies for Children With Inflammatory Bowel Disease: Develop Registry DataRobert N. Baldassano, Harland S. Winter, Anne M. Griffiths et al.|Gastroenterology|2013Cited by 8
833 Malignancies in Children Receiving Infliximab and Other Inflammatory Bowel Disease Therapies: An Inflammatory Bowel Disease Multicenter, Prospective, Long-Term Registry of Pediatric Patients (Develop) Registry DataRichard B. Colletti, Gigi Veereman, Salvatore Cucchiara et al.|Gastroenterology|2013Cited by 7
15 Serious infections and associated risk factors in patients receiving infliximab and immunotherapies for children with inflammatory bowel disease: DEVELOP registry dataR Baldassano, Harland S. Winter, Richard B. Colletti et al.|Journal of Crohn s and Colitis|2013Cited by 3
P436 Malignancies in children receiving infliximab and other inflammatory bowel disease therapies: an inflammatory bowel disease multicenter, prospective, long-term registry of pediatric patients (DEVELOP) registry dataRichard B. Colletti, Gigi Veereman, Linda Tang et al.|Journal of Crohn s and Colitis|2013Cited by 3